{
      "StudyFieldsResponse": {
            "APIVrs": "1.01.05",
            "DataVrs": "2022:10:06 23:25:58.836",
            "Expression": "NCT03252535",
            "NStudiesAvail": 430108,
            "NStudiesFound": 1,
            "MinRank": 1,
            "MaxRank": 1000,
            "NStudiesReturned": 1,
            "FieldList": [
                  "OtherEventStatsGroupId",
                  "OtherEventStatsNumAffected",
                  "OtherEventStatsNumAtRisk",
                  "OtherEventStatsNumEvents",
                  "OtherEventTerm",
                  "OtherOutcomeDescription",
                  "OtherOutcomeMeasure",
                  "OtherOutcomeTimeFrame",
                  "OutcomeAnalysisCILowerLimit",
                  "OutcomeAnalysisCILowerLimitComment",
                  "OutcomeAnalysisCINumSides",
                  "OutcomeAnalysisCIPctValue",
                  "OutcomeAnalysisCIUpperLimit",
                  "OutcomeAnalysisCIUpperLimitComment",
                  "OutcomeAnalysisDispersionType",
                  "NCTId"
            ],
            "StudyFields": [
                  {
                        "Rank": 1,
                        "OtherEventStatsGroupId": [],
                        "OtherEventStatsNumAffected": [],
                        "OtherEventStatsNumAtRisk": [],
                        "OtherEventStatsNumEvents": [],
                        "OtherEventTerm": [],
                        "OtherOutcomeDescription": [
                              "Will be carefully evaluated from the periodical assessments including clinical, laboratory, and imaging exams, so that any change is properly recorded.",
                              "This parameter will be evaluated by statistical comparison of NF-L (biological marker) results observed at baseline period and other analysed times. The results will be correlated to UHRDS scores."
                        ],
                        "OtherOutcomeMeasure": [
                              "Safety administration of Cellavita HD product",
                              "Prognosis of Huntington Disease"
                        ],
                        "OtherOutcomeTimeFrame": [
                              "monthly for fourteen months",
                              "baseline and one year later"
                        ],
                        "OutcomeAnalysisCILowerLimit": [],
                        "OutcomeAnalysisCILowerLimitComment": [],
                        "OutcomeAnalysisCINumSides": [],
                        "OutcomeAnalysisCIPctValue": [],
                        "OutcomeAnalysisCIUpperLimit": [],
                        "OutcomeAnalysisCIUpperLimitComment": [],
                        "OutcomeAnalysisDispersionType": [],
                        "NCTId": [
                              "NCT03252535"
                        ]
                  }
            ]
      }
}